Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
Abstract Background Although concurrent chemoradiotherapy (CRT), as one of the most effective antineoplastic therapies in clinic, can successfully inhibit the growth of tumor cells, a risk of developing secondary tumor is still an insurmountable barrier in clinical practice. Results Herein, a new pl...
Main Authors: | Wei Jiang, Lulu Wei, Bing Chen, Xingyu Luo, Peipei Xu, Jianfeng Cai, Yong Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-03-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-022-01322-y |
Similar Items
-
Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
by: Wei Jiang, et al.
Published: (2022-05-01) -
Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
by: Qiuji Wu, et al.
Published: (2021-10-01) -
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
by: Satomi Hattori, et al.
Published: (2021-04-01) -
Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
by: Fubin Zhu, et al.
Published: (2023-09-01) -
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
by: Daniil Spector, et al.
Published: (2021-04-01)